Track Achieve Life Sciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Achieve Life Sciences, Inc. ACHV · Stock Open Achieve Life Sciences, Inc. in new tab

6.71 USD
EPS
-1.71
P/B
-47.41
ROE
-844.99
Beta
2.41
Target Price
14.15 USD
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
EPS-1.71
Book Value-0.14
Price to Book-47.41
Debt/Equity140.03
% Insiders0.908%
Estimates
Forward P/E-10.39
Forward EPS-0.65
Target Mean Price14.15

DCF valuation

Model fair value for Achieve Life Sciences, Inc. (ACHV)
Result
Sign in to run the valuation for ACHV.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus None · mean target 14.15 USD (low 9.00, high 21.00) · as of 10 Nov 2026
Low 9.00
Mean 14.15
High 21.00
Price 6.71
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Achieve Life Sciences, Inc. Logo Achieve Life Sciences, Inc. Analysis (ACHV)

Canada Health Care Official Website Stock

Is Achieve Life Sciences, Inc. a good investment? Achieve Life Sciences, Inc. (ACHV) is currently trading at 6.71 USD. Market analysts have a consensus price target of 14.15 USD. This suggests a potential upside from current levels.

Earnings Schedule: Achieve Life Sciences, Inc. is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is -0.65.

Investor FAQ

Does Achieve Life Sciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Achieve Life Sciences, Inc.?

Achieve Life Sciences, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of -1.71.

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Exchange Ticker
FRA (Germany) SP4P.F
NMS (United States) ACHV
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 21, 2008 0.06
Aug. 3, 2017 0.09
May 24, 2018 1:10
July 31, 2020 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion